Back to top

Ahead of Wall Street

Read Full ArticleHide Full Article
Monday, August 4, 2014

(This is Mark Vickery covering for Sheraz Mian, who is off today.)

After the market sell-off last week, the S&P 500 is now down 3% from its rally-highs a month ago. A Goldilocks jobs report, which is not now expected to sway the Fed into any new drastic policy changes, was a bit of good news Friday, even though the S&P was hit by a mid-day swoon it wouldn’t quite recover from.

Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data. Now that earnings strength is being realized, it’s time to harvest some of that growth — thus the market was down last week. Add in plenty of instability in various regions around the globe — Argentina, Ukraine, Gaza — and it’s become a good time to take a breather.

Every good investor knows no gravy train lasts forever. And the key to the next big leg up, when it happens, will be what’s establishing itself now; guidance for Q3 and beyond is and will continue to be key.

If a stock is currently a Zacks Rank #1, chances are it outperformed in its most recent quarter and guided higher for the next quarter and fiscal year. Here are three Zacks Rank #1 stocks with upwardly revised analyst estimates, and whether they are up or down over the past month:

  • Con-way — upwardly revised for Q3, Q4, FY14 and FY15; down 2.6%
  • Capital One (COF - Free Report) — upwardly revised for Q3, Q4, FY14 and FY15; down 6.4%
  • First Solar (FSLR) — upwardly revised for FY14; down 10.75%

Elsewhere this morning, Amgen (AMGN - Free Report) reported positive late-stage data on Kyprolis, a treatment for relapsed multiple myeloma. Shares of this Zacks Rank #3 company are up 3.5% in today’s pre-market.

Mark Vickery
Senior Editor

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

The full Ahead Of Wall Street article

Capital One Financial Corporation (COF) - free report >>

Amgen Inc. (AMGN) - free report >>